Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid Services

Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for
Medicare and Medicaid Services

Cesca Therapeutics Invited by the Alliance for Regenerative Medicine to
Present Case Study to CMS for Treating Critical Limb Ischemia With
SurgWerks(R) - CLI Cell Therapy

RANCHO CORDOVA, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics
Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company,
today announced the presentation to the Centers for Medicare and Medicaid
Services ("CMS") of its case study highlighting the potential clinical benefit
and cost savings of its SurgWerks^®-CLI cell therapy for treatment of
non-operable Critical Limb Ischemia ("CLI"). Ken Harris, President of Cesca
Therapeutics, participated along with other regenerative medicine industry
representatives, and presented one of two case studies in the presentation
organized and led by the Alliance for Regenerative Medicine ("ARM"), a global
advocacy organization that promotes legislative, regulatory, reimbursement,
investment, technical and other initiatives to accelerate the development of
safe and effective regenerative medicine technologies.

Cesca was honored to participate with ARM and its fellow members in
establishing dialogue with CMS as the agency begins evaluating this new field
of medicine. Key messages delivered were the potential curative nature of
regenerative therapies being developed by ARM's members like Cesca, and
Cesca's SurgWerks-CLI therapy was highlighted as an example which has the
potential to deliver such promise in no-option critical limb ischemia

CLI is the most severe form of Peripheral Arterial Disease ("PAD") affecting
over 2 million patients in the United States. It is often associated with
chronic foot and leg ulcers leading to approximately 200 thousand amputations
per year. A diagnosis of CLI statistically results in a 25% mortality rate and
a 25% amputation rate within one year. The cost of CLI-related amputations to
Medicare is estimated by the Sage Group to be $25 billion per year. The
current standard of care for CLI is surgical revascularization which is
expensive, highly invasive and often fails to restore proper blood supply to
the patient's affected limb(s).

Cesca Therapeutics has developed a cellular therapy currently in clinical
trials to treat patients with CLI that has the potential to significantly
mitigate the disease symptoms, including saving the legs of certain patients
and has the potential to reduce the current cost of CLI by billions of
dollars. In its case study to CMS, the Company highlighted the results of its
Phase I/II clinical trial treating 17 patients with CLI with its SurgWerks-CLI
cell therapy. "We experienced an 82% major amputation free rate in the
Intent-To-Treat patients, and significant reductions in hard clinical
endpoints including VAS pain scores and a meaningful improvement in the 6
minute walk test," said Ken Harris, President of Cesca Therapeutics. "We
enjoyed the opportunity to discuss with CMS representatives our unique
clinical approach to treating this devastating disease using our proprietary
bone marrow derived stem cell therapy, and our plans for conducting the
pivotal trial," continued Harris.

The SurgWerks-CLI proprietary 60 minute process includes:

  *Harvesting a patient's own bone marrow with a stem cell optimized trocar
  *Testing the stem cells real time for dose and quality using Cesca's
    proprietary Q-Cyte diagnostic device
  *Using Cesca's proprietary smart vision system (called the VXP) to select a
    patient specific therapeutic stem cell dose
  *Delivering the therapeutic stem cell dose into the targeted angiosomes of
    the patient's leg using Cesca's proprietary tissue infusion needle

"We have developed our SurgWerks-CLI cell therapy to optimize the cell
harvesting, selection and delivery of a patient's own stem cells in a
procedure administered within 60 minutes right at the patient's bedside," said
Matthew Plavan, CEO of Cesca Therapeutics."This clinical approach is a key
differentiating element of our unique commercialization strategy that we
believe will result in significant adoption of our SurgWerks therapy with a
cost point targeted to be below the current standard of care, thereby
significantly reducing the cost of care for CLI patients," continued Plavan.
"Another critical element of our commercialization strategy is understanding
medical coverage and reimbursement criteria as early in the clinical
development cycle as possible in both the private payer and CMS reimbursement
programs," said Plavan.

Based on the compelling early efficacy results observed in the Cesca's Phase
I/II clinical trial treating no option CLI patients, the Company is pursuing
FDA approval to conduct a pivotal (Phase III) trial under an IDE regulatory
pathway in the first half of 2015.

About Cesca Therapeutics

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the
research, development, and commercialization of autologous cell-based
therapeutics for use in regenerative medicine.We are a leader in developing
and manufacturing automated blood and bone marrow processing systems that
enable the separation, processing and preservation of cell and tissue therapy
products.These include:

  *SurgWerks™ Platform, a proprietary stem cell therapy point-of-care kit
    system for treating vascular and orthopedic indications that integrate the
    following indication specific systems:

  - Cell harvesting

  - Cell processing and selection

  - Cell diagnostics

  - Cell delivery

  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood.
  *The MarrowXpress Platform (MXP), a derivative product of the AXP and its
    accompanying disposable bag set, isolates and concentrates stem cells from
    bone marrow. Self-powered and microprocessor-controlled, the MXP contains
    flow control optical sensors that volume-reduces blood from bone marrow to
    a user defined volume in 30 minutes, while retaining over 90% of the MNCs.
  *The Res-Q™ 60 (Res-Q), a point-of-care system designed for the preparation
    of cell concentrates, including stem cells, from bone marrow aspirates and
    whole blood for platelet rich plasma (PRP).
  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.

Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking
statements include but are not limited to that Cesca Therapeutics Inc. will
provide unmatched world-class capability and service to its clients. These
statements involve risks and uncertainties that could cause actual outcomes to
differ materially from those contemplated by the forward-looking statements. A
more complete description of risks that could cause actual events to differ
from the outcomes predicted by our forward-looking statements is set forth
under the caption "Risk Factors" in Cesca Therapeutics annual report on Form
10-K and other reports we file with the Securities and Exchange Commission
from time to time, and you should consider each of those factors when
evaluating the forward-looking statements.

CONTACT: Cesca Therapeutics Inc.
         Website: http://www.cescatherapeutics.com
         Investor Relations
         +1-916-858-5107, or

Cesca Therapeutics Inc. logo
Press spacebar to pause and continue. Press esc to stop.